Zai Lab Limited (HKG:9688)
24.18
+1.14 (4.95%)
Sep 5, 2025, 4:08 PM HKT
Zai Lab Employees
Zai Lab had 1,869 employees as of December 31, 2024. The number of employees decreased by 306 or -14.07% compared to the previous year.
Employees
1,869
Change (1Y)
-306
Growth (1Y)
-14.07%
Revenue / Employee
1.80M HKD
Profits / Employee
-892.60K HKD
Market Cap
26.04B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1,869 | -306 | -14.07% |
Dec 31, 2023 | 2,175 | 139 | 6.83% |
Dec 31, 2022 | 2,036 | 85 | 4.36% |
Dec 31, 2021 | 1,951 | 757 | 63.40% |
Dec 31, 2020 | 1,194 | 502 | 72.54% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
BeOne Medicines AG | 11,000 |
Hansoh Pharmaceutical Group Company | 8,989 |
JD Health International | 3,564 |
Innovent Biologics | 5,659 |
Sino Biopharmaceutical | 24,379 |
WuXi Biologics | 12,575 |
Akeso | 3,035 |
CSPC Pharmaceutical Group | 21,400 |
Zai Lab News
- 2 days ago - Amgen dips after trial update for Zai Lab partnered gastric cancer therapy - Seeking Alpha
- 3 days ago - Zai Lab Ltd (ZLAB) Secures Approval for TIVDAK in Hong Kong | ZLAB stock news - GuruFocus
- 3 days ago - Zai Lab Announces Approval of TIVDAK® for Patients with Recurrent or Metastatic Cervical ... - GuruFocus
- 3 days ago - Zai Lab Announces Approval of TIVDAK® for Patients with Recurrent or Metastatic Cervical Cancer in Hong Kong - Business Wire
- 8 days ago - Zai Lab Announces Participation in Investor Conferences in September 2025 - Business Wire
- 17 days ago - Zai Lab Announces China National Medical Products Administration Grants Innovative Medical Device Designation for Tumor Treating Fields for Patients with Pancreatic Cancer - Business Wire
- 23 days ago - Zai Lab Establishes Oncology Scientific Advisory Board - Business Wire
- 4 weeks ago - Zai Lab reaffirms $560M-$590M 2025 revenue target as VYVGART and pipeline drive growth - Seeking Alpha